This presentation emphasizes the importance, as well as the utility, of application of tools across scales typically encountered in a process R&D setting, and provides perspective on future directions the team at Merck is moving.
Who Should View This Presentation?
Chemists and Engineers doing chemical development in Pharmaceutical and High-Value Chemical Development.
Leverage Technology to Push Forward During a Pandemic
Since its inception in 2014, Merck's Process Development Intensification Laboratory (iLab) within Small Molecule Process Research & Development has been focused on the development of tools and techniques to enable acquisition of deeper, more fundamental process understanding in a resource sparing manner. This is centered around the concept of data intensification, specifically, around enabling more efficient data capture, data reduction and data analysis. We have grown to call these activities Data-Rich Experimentation (DRE) and investments have spawned a broader strategic initiative, across large and small molecule Process R&D, called "the DRE Initiative".
This presentation highlights the installation of novel, enabling technologies, such as process modeling, bench-top automation, medium and high-throughput experimentation, process analytical technologies (PAT) and statistically designed experimentation. We look back on:
- The development, demonstration, and the deployment of novel tools designed to increase the information density of the experiments we conduct
- The efficiency of the chemists and engineers who conduct data rich experimentation (DRE)
- How enabling technologies were leveraged to continued research efforts during the pandemic
Join the hundreds of researchers who already viewed this presentation.